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Document This  document  has  been  prepared  for  use  within  the  Commission.  It  does  not 
necessarily  represent  the  Commission•s  official position. This  notice  which  has  no  Legal  force  has  been  prepared  by  the 
Committee  for  Proprietary  Medicinal  Products  in  consultation 
with  the  competent  authorities  of the  Member  States,  in  order  to 
provide  general  guidance  on  the  use  of  the  new  multi-State 
procedure  for  applying  for  marketing  authorisation.  In  cases 
of doubt,  reference  should  be  made  to  the  relevant  Community 
directives. I.  FOREWORD 
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I.  FOREWORD 
Since  1977,  persons  responsible  for  marketing  proprietary  medicinal 
products  have  been  able  to  use  an  alternative procedure  in  order 
to  obtain  authorization to  market  their  products  within  the  Member 
States  of  the  European  Communities.  Instead of  submitting  separate 
applications  directly to  the  competent  authorities  of  each  Member 
State  in  which  the  product  is  to  be  marketed,  they  have  been  able 
to  submit  a  common  application to  five  or  more  Member  States  using 
the  Committee  for  Proprietary Medicinal  Products  (hereinafter  CPMP) 
attached to  the  Commission  of  the  European  Communities,  after  first 
having  obtained  a  marketing  authorization  in one  Member  State. 
FoLLowing  the  entry  into  force  of  Council  Directive  83/570/EEC  in 
November  1985,  major  changes  are  made  to  the  Community  procedures, 
the  minimum  number  of  Member  States  to  which  a  common  application 
may  be  made  is  reduced  from  five  to  two,  and  the  Member  States  to 
which  the  application  is  addressed  must  take  the  the  authorization 
granted  by  the  original  Member  State  into due  consideration. 
This  notice  describes  the  administrative  steps  to  be  followed  when 
applying  for  marketing  authorization  (hereinafter  MA)  through  the 
new  Community  procedure  and  provides general  guidance  on  the  manner 
in  which  applications  should  be  presented.  This  notice  cancels  and 
replaces  the earlier notices  published  in  the Official  Journal  of 
the  European  Communities  (OJ  No.  C 302/6 of  15.12.77  and  OJ  No. 
c 162/3  of  2.7.80). 
The  rules governing  proprietary  medicinal  products  for  human  use 
have,  to  a  Large  extent,  been  harmonized  within  the  Member  States 
of  the  European  Community"  These  rules,  which  apply  equally  to 
applications  for  MA  submitted  through  purely  national  procedures 
and  to  applications  submitted  through  Community  procedures,  are 
contained  in  the  following  Legal  texts: 
-Council  Directive  65/65/EEC  of  26.1.1965  relating  to proprietary 
medicinal  products  (OJ  No.  22,  9.2.1965) 
. I . - 3  -
- Council  Directive  75/318/EEC  of  20.5.1975  relating  to  analytical, 
pharmaco-toxicological  and  clinical  standards  and  protocols  in 
respect  of  the  testing  of proprietary  medicinal  products 
(OJ  L 147  of  9.6.1975) 
-Council  Directive  75/319/EEC  of  20.5.1975  relating  to proprietary 
medicinal  products  (OJ  L  147  of  9.6.1975) 
-Council  Directive  83/570/EEC  of  26.10.1983  amending  Directives 
65/65/EEC,  75/318/EEC  and  75/319/EEC  relating  to proprietary 
medicinal  products  (OJ  L 332  of  28.11.1983) 
Council  Recommendation  83/571/EEC  of  26.10.1983  concerning  tests 
relating  to  the  placing  on  the  market  of  proprietary  medicinal 
products  (OJ  L 332  of  28.11.1983) 
- Council  Directive  78/25/EEC  of  12.12.1977 relating  to  the  colouring 
matters  which  may  be  added  to  medicinal  products  (OJ  L  11  of  14.1.1978) 
These  texts  may  be  obtained  from  national official publication 
offices  or  from  the  "Office  des  publications officielles  des 
Communa ute s  europe enne s",  L  -2985  Luxembourg,  tel.  49  DO  81, 
Postal  cheque  account:  19  190-81  -Bank  current  account: 
B.I.L.  8-109/6003/200;  Citibank  Brussels:  570-1121200-35; 
Sogenal  Luxembourg:  04-3-2600-490226  (*)~ 
A brochure  entitled "The  Rules  governing  Medicaments  in  the  European 
Community"  contains  the  full  texts  of  all  the  relevant  Community  Law 
before  1.1.85,  and  is  available  from  the  same  addresses 
(ISBN  92-825-4531-8;  EC  catalogue  No.  CB-41-84-515-EN-C). 
..1 .. 
(*)  In  September  1984,  the  Commission  of  the  European  Communities  put 
forward  a  series  of  proposals  to  amend  some  of  the  above  mentioned 
texts  (see  OJ  No.  c 293  of  5.11.84).  At  the  time  of  going  to  press, 
~odifications to  these  proposals  ~ere submitted  on  4  (iarch  1986 
( COI·H86) 117). - 4  -
II. PURPOSE  AND  SCOPE  OF  THE  NEW  MULTI-STATE  (CPMP)  PROCEDURE 
The  Legal  rules  governing  the  new  Community  procedure,  which  is  subsequent-
Ly  referred  to  as  the  "multi-state"  procedure,  are  set  out  in  Chapter  III 
of  Directive  75/319/EEC,  as  amended  by  Directive  83/570/EEC. 
Applications  must,  if necessary,  be  updated  to  comply  with  the  rules 
in  force  at  the  time  of  submission. 
The  primary  purpose  of  the  multi-state  procedure  is to  make  it easier 
for  a  person  who  has  already obtained  a  MA  in  one  of  the  Member  States 
to get  further  MAs  for  the  product  concerned  in  two  or  more  of  the other 
Member  States.  On  the basis  of the  same  complete  documentation,  and  taking 
the  MA  granted  by  the  first  Member  State  into  due  consideration,  the 
authorities of  the  Member  States  to  which  the  application is addressed 
have  120  days  to  put  forward  their  reasoned  objections  to the  CPMP. 
If  no  objections  are  Lodged  within  this  time  Limit,  each  Member  State 
concerned  has  granted  MA  and  the  applicant  will  be  informed  accordingly. 
Where  one  or  more  objections  are  advanced,  the  matter  is  referred  to  the 
CPMP  which  considers  the grounds  for  the objections  and  any  written or 
oral  explanations  provided  by  the  applicant  before  issuing  its own 
reasoned  opinion,  normally  within  a  period  of  60  days.  This  opinion  is 
addressed  to  the  Member  States  concerned.  Within  a  further  60  days  they 
must  decide  on  what  action to  take  pursuant  to  the  Committee's  opinion 
and  must  inform  the  CPMP  of  their decision. 
Certain  categories  of  proprietary  medicinal  products  may  not  benefit 
from  this  procedure,  because  they  are  not  yet  covered  by  the  Community 
directives:  vaccines,  toxins,  sera,  products  based  on  human  blood  or 
blood  constituents,  radioactive  isotopes,  homeopathic  medicines 
(Article  34  of  Directive  75/319/EEC). 
In  addition,  the  multi-state application  must  relate  to  a  proprietary 
medicinal  product  which  has  been  authorized  by  one  Member  State  in 
accordance  with  the  criteria  Laid  down  by  the  Community  directives. 
Thus  products  marketed  by  virtue of  previous  national  provisions  are 
not  covered  by  the  new  procedures  unless  their quality,  safety  and 
efficacy  have  been  reviewed  in  accordance  with  Article  39  of  Directive 
75/319/EEC. - 5 -
III"  NEW  DRUG  APPLICATIONS  AND  ABRIDGED  APPLICATIONS 
The  multi-state  procedure  may  be  used  not  only  for  new  drug  applications 
but  also  for  abridged  applications  submitted  pursuant  to point  8  of 
Article  4  of  Directive  65/65/EEC"  However,  the  submission  of  abridged 
applications  through  the multi-state  procedure  may  give  rise to 
particular difficulties  and  the  attention of  applicants  is  specifically 
drawn  to  four  points" 
i)  The  fact  that  in  one  Member  State  a  given  substance  is sufficiently 
well-known  for  an  abridged  application  to  be  acceptable  does  not 
necessarily  imply  that  the  same  is true of all the other  Member 
States"  In  certain  Member  States  there  may  be  no  experience  of  the 
medicinal  use  of  the  product  and  complete  documentation  may 
therefore  be  required" 
ii)  The  experts  reports  submitted  in  connection  with  an  abridged 
application  must  clearly  state the  grounds  for  using  published 
references  under  the  conditions  set  out  in  Directive  75/318/EEC 
(see  Art"  2(c)  of  Directive  75/319/EEC)" 
iii)  The  pt·ovisions  of  Council  Directive  75/318/EEC  on  the  analytical, 
pharmaco-toxicological  and  clinical  standards  and  protocols  in 
respect  of  the  testing  of  proprietary  medicinal  products  apply  in 
like  manner  to  references  to  published  data  submitted  pursuant 
to  Article  4  point  8  of  Directive  65/65/EEC  (Art"  1 of  Directive 
75/318/EEC)" 
iv)  Where  necessary,  bioavailability studies  must  be  undertaken 
(Annex  to  Directive  75/318/EEC  as  amended,  Part  3,  Chapter  II  A, 
paragraph  5)~ - 6-
IV"  SUBMISSION  OF  THE  MULTI-STATE  APPLICATION 
The  person  responsible  for  placing  the  product  on  the  market  submits 
an  application directly  to  the  competent  authorities of each  of the 
two  or  more  Member  States  concerned,  referring to the  procedure  Laid 
down  in  Chapter  III of  Directive  75/319/EEC,  as  amended  by  Directive 
83/570/EEC" 
Each  application  should  be  accompanied  by  the  documents  referred to 
in  Articles  4,  4(a)  and  4(b)  of  Directive  65/65/EEC" 
The  applicant  should  also testify that  each  dossier  is  identical to 
that  accepted  by  the  first  Member  State,  or  when  necessary,  he  should 
specify  any  additions  or  modifications that  have  been  made" 
In  addition,  he  should  indicate  whether  an  application to market  the 
proprietary medicinal  product  has  been  made  to or granted  by  any  other 
Member  State  under  purely national  procedures" 
The  applicant  notifies  the  Secretariat  of  the  CPMP  of  the  multi-
state  application,  informs  it  of  the  Member  States  concerned  and 
of the  dates  on  which  the  dossiers  were  sent  to those  Member  States 
and  sends  it  a  copy  of  his  authorization,  including  the  summary 
of  the  product  characteristics approved  by  the  first  Member  State 
<Article  4(b)  of  Directive  65/65/EEC)" 
In  addition  the  applicant  should  inform  the  competent  authority  of 
the  Member  State  which  granted  the  initial  authorization  of  the 
application  and  of  any  additions  made  to  the original  dossier" 
This  authority  may  require  the applicant  to  provide  such  information 
and  documents  as  are  necessary  to  enable  it to  check  the  identity 
of  the  dossier  filed  under  the  multi-state  procedure  with  the  dossier 
on  which  it  took  its  own  decision" - 7  -
As  soon  as  all the  Member  States  concerned  have  confirmed  receipt 
of  the  application,  the  Secretariat notifies all the  Member  States 
and  the  applicant  of  the  start  of  the  120  day  period  referred to 
in  Article 9(3)  of  Directive  75/319/EEC  as  amended~ 
No  specific  fee  is payable  in  respect  of  the  work  of  the  CPMP,  but 
national  registration  fees  remain  payable  in  accordance  with  the 
rules  of  the  Member  State  concerned~ 
In  accordance  with  Article  13  of  Directive  75/319/EEC  as  amended,  immedia-
tely  a  multi-state  application  is  Lodged  the  competent  authority of the 
Member  State  which  granted  the  initial  application  is  required  to 
communicate  a  copy  of  any  assessment  report  relating  to the particular 
product  to the  Member  States  concerned  by  the  application~ 
Persons  preparing  a  multi-state  application  are  therefore  strongly 
advised  to  contact  this  authority  at  an  early  stage to  make  the 
administrative  arrangements  necessary  to  ensure  that  any  necessary 
translations  of  the  assessment  report  into  a  Language  or  Languages 
acceptable  to the  countries  concerned  by  the  application  are  available 
at  the  same  time  as  they  formally  submit  the  application~ The  applicant 
will  be  expected  to  pay  any  translations of  the  assessment  report 
which  are  necessary  to  consider  his  application"  In  order  to  reduce 
these  costs to  a  minimum,  all  the  competent  authorities except  the 
French  authorities  have  indicat~d that  they  are  prepared  to ·accept 
official  assessment  reports  in  English  if they  are  notavailable  in 
their  own  national  Language~ - 8  -
The  names,  addresses,  telex  and  telephone  numbers  of  the  competent 
authorities of  the  Member  States  are: 
Belgium: 
Denmark: 
Germany: 
France: 
Greece: 
Ireland: 
Italy: 
Luxembourg: 
Ministere  de  La  Sante  publique 
Inspection generale  de  La  Pharmacie 
Cite  Administrative,  Quartier  Vesale 
1  0  1  0  B  r  L~ x  e L  l e s 
Tel":  (2)  210,.49,.00  and  210,.49,.01 
Telex:  25"768  MVGSPF  B 
Sundhedsstyrelsen,  Farmaceutiske  Laboratorium 
Frederikssundsvej  378 
DK-2700  Br0nsh0j 
Tel":  (2)  94 .. 37"73 
Telex:  35333  IPHARM  DK 
Institut  fur  Arzneimittel  des 
Bundesgesundheitsamtes 
Seestr"  10 
D-1000  Berlin  65 
Tel .. :  (30)  450"22 .. 03 
Telex:  183310  BGESA  D 
Ministere  des  Affaires  sociales  et  de  La 
Solidarite nationale 
Direction  de  La  Pharmacie  et  du  Medicament 
1,  place  de  Fontenoy 
F-75700  Paris 
Tel":  567"55"44 
Telex:  250011  SANTSEC  F 
E"O"F ..  <National  Drug  Organisation) 
Voulis  Str  ...  4 
Athens  10562 
Tel ... :  323 .. 09..,11 
Telex:  223514 
National  Drugs  Advisory  Board 
63-64  Adelaide  Road 
Dublin  2 
Tel .. :  76"49 .. 71  - 7 
Telex:  90542 
Ministero  della  Sanita 
Servizio  Farmaceutico 
Viale della  Civilta  Romana,  7 
I-00144  ROMA,  EUR 
Tel ..  (6)  592"58 .. 63  and  592..,58,.24 
Telex:  610453  MINSAN  I 
Direction de  La  Sante 
Division de  La  Pharmacie  et  des  Medicaments 
10,  rue  C"M"'  Spoo 
L-2546  Luxembourg 
Tel":  (352)  4"08 .. 01 
Telex:  2546  SANTE  LU 
.. ! .. Netherlands: 
United  Kingdom: 
Spain: 
Portugal:  (.,q 
- 9  -
College  ter  beoordeling  van  geneesmiddelen 
P.O.Box  5811 
NL-2280  HV  Rijswijk 
Tel.:  (70)  94.95.05 
Telex:  32691  VMRWK  NL 
Department  of  Health  and 
Medicines  Division 
Market  Towers 
1  Nine  Elms  Lane 
London  SW8  5NQ 
Tel.:  ( 1)  720.21.88 
Telex:  883669  DHSSHQ  G 
Social  Security 
Ministerio  de  Sanidad  y  Consume 
Direccion  General  de  Farmacia  y 
Productos  Sanitarios 
Paseo  del  Prado,  18-20 
E-28014  Madrid 
Tel.:  467.34.28 
Telex:  22.608  MSASS 
Ministerio  da  Saude 
Direccao  Geral  dos  Assuntos  Farmaceuticos 
Av.  Estados  Unidos  da  America,  37 
Tel. :  80. 41 • 31 
Telex:  15655  MAS  P 
The  address  of  the  Secretariat  of  the  CPMP  is: 
D.G.  III  A 3 
11Pharmaceuticals,  veterinary  medicines" 
Commission  of  the  European  Communities 
Rue  de  La  Loi  200 
B-1049  Brussels 
Tel.:  235~51.80 I  235.69.35 
Telex:  21.877  COMEU  8 
(*)  For  applications  concerning  Portugal,  see  page  11. - 10  -
V.  PRESENTATION  OF  THE  MULTI-STATE  APPLICATION 
1.  Order  of  presentation  and  content  of  the  dossier 
Detailed guidance  on  the presentation of  the different  parts of 
a  multi-state  application  is given  in  the  Annex  I. Although  it  has 
no  Legal  force,  this  guidance  has  been  prepared  in  consultation 
with  the  competent  authorities  of  all  the  Member  States,  in  order 
to facilitate the  examination of the  application~ 
2.  Expert  reports 
In  accordance  with  Directive  75/319/EEC,  Article  2,  the  pharmaceutical, 
pharmaco-toxicological  and  clinical parts of  the  complete  dossier 
should  each  include  an  expert  report.  It  is  important  to  emphasize 
that  well  prepared  expert  reports greatly facilitate the  task  of  the 
competent  authorities  in  evaluating  the  dossier  and  contribute 
towards  the  speedy  processing  of  applications.  For  these  reasons 
particular  care  should  be  taken  in  the  preparation of  the  experts 
reports,  and  the  guidance  contained  in  Annex  II  should  be  followed. 
Where  relevant  Community  guidelines  on  the  conduct  of  tests  and 
trials on  a  proprietary medicinal  product  exist,  these  should  be 
taken  into  consideration  when  the  report  is prepared  and  any  deviation 
from  them  should  be  discussed  and  justified.  A List  of  the guidelines 
currently  available is  included  in  Section  IX  of this  Note~ 
3.  Summaries  of the  dossier 
Where  in  addition  to  copies  of  the  complete  dossier  a  Member  State 
concerned  by  an  application  requires  the  submission  of  additional 
copies  of  summaries  of  the  dossier,  these  should  consist  of  the 
summary  of  product  characteristics proposed  by  the  applicant 
<Article  4(a)  of  Directive  65/65/EEC  as  amended)  bound  together 
with  the  experts  reports  on  the three  parts  of  the  dossier: 
pharmaceutical,  pharmaco-toxicological  and  clinical  (1)~ 
• I . 
(1)  For  applications  concerning  the  United  Kingdom,  however,  the  analytical 
report  should  be  bound  separately  from  the other  two  parts. 4.  Number  of  copies  and  accepted  Languages 
Information  on  the  number  of  copies  of  the  application to  be 
submitted  to  the  authorities  of  each  Member  State  and  on  the 
Languages  in  which  applications  should  be  drafted  is  set  out 
in  the  table on  the  following  page.  Further  copies  of  the  application 
may  be  required  by  the  authorities  in  certain exceptional  cases~ 
5.  Specimens  and  Samples 
In  accordance  with  Article  4,  second  paragraph,  point  9,  of  Directive 
65/65/EEC  as  amended,  a  specimen  or  mock  up  of  the  sales presentation 
of  the  proprietary product,  together  with  a  package  Leaflet  where  one 
is to  be  enclosed,  must  be  included  in  each  complete  dossier  submitted. 
Moreover,  for  the  purposes  of  implementing  Article  4  of  Directive 
75/319/EEC,  samples  of  the  active  principles  and  of  the  finished 
product  must  be  supplied  as  a  matter  of  course  to the  competent 
authorities  in  Belgium,  Greece,  Ireland,  Italy,  Luxembour~  Spain  and 
the  Netherlands.  For  02lgiur.1  and  Spain.  samqlcs  uill also  be  required 
of  other  starting  mJt2rials  in  respect  of  which  the  applicant  has 
introduced  a  nonoGrcph.  In  other  cases~  samples  should  be  provided 
at  the  request  of  the  competent  ~uthorities. 
6.  Applications  concerning  Portugal 
In  accordance  with  the  terms  of  the  Act  of  Accession,  Portugal  is  not 
required  to  implement  Council  Directives  65/65/EEC,  75/318/EEC, 
75/319/EEC,  78/25/EEC  and  83/570/EEC  until  1  January  1991. 
Unless  the  Portuguese  authorities  indicate otherwise,  applications  to 
market  a  medicinal  product  in  Portugal  should  therefore  be  submitted 
in  accordance  with  national  procedures  and  the  multi-State  procedure 
should  not  be  used. 
However  the  Portuguese authorities  have  indicated that  they  will  accept 
applications  presented  in  accordance  with  the  standard  Community  format 
described  in this  Notice  to  Applicants.  Two  complete  dossiers  are  re-
quired  together  with  two  summaries  and  six  additional  copies  of 
Part  III  <Toxicological  and  Pharmacological)  and  Part  IV  (Clinical). 
The  basic  data  in  Parts  III  and  IV  may  be  presented  in  English  or 
French  provided  they  are  accompanied  by  a  very  detailed  and  precise 
synthesis  in  Portuguese  containing,  in  particular,  references  to  the 
p  a~  e s  con t a i n i n  r;  t h  c  c1 a t a  i n  ~; u  e s t i on • 
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VI~  CASES  WHERE  A CPMP  OPINION  IS  REQUIRED 
As  noted  above,  an  opinion  of  the  CPMP  is  not  required  for  every 
multi-state  application~ If no  Member  State  has  put  forward 
reasoned  objections  during  the  120  day  period  allowed  for 
national  examination of  the  application,  marketing  authorisation 
has  been  granted  by  each  of  the  Member  States  concerned~ 
If,  however,  one  or  more  of  the  Member  States  concerned  does  Lodge 
reasoned  objections  to  the  application  within the  120  days,  the ob-
jections  are  formally  notified to  the  applicant  by  the  authority  concerned 
and  the  matter  is  referred  to  the  CPMP  for  its  opinion~ In  this  case  the 
applicant  is  required  to  send  to  the  Secretariat of  the  Committee 
a  complete  copy  of  the  application together  with 13  copies  of  the 
summaries  as  soon  as  possible after the  receipt  of  reasoned  ob-
jections  from  a  Member  State~  Although  the  complete  dossier  may 
be  submitted  in  English  or  French,  it  will  greatly facilitate  the 
work  of  the  Committee  if  copies  of  these  summaries  are  made  available 
in  both  English  and  French~  At  the  same  time  copies  of  any  existing 
assessment  reports  will  be  circulated to all the  Member  States~ 
The  Committee  is  required  to give  its opinion 
within  60  days  of  the  date  on  which  the  matter  was  referred to it, 
that  is the  date  of  the  expiry  of  the  120  day  period  for  national 
examination  of  the  application~  As  soon  as  possible after the 
receipt  of  reasoned  objections  from  a  Member  State,  the  Secretariat 
of  the  Committee  will  notify  the  applicant  of  the  date on  which 
the  Committee  proposes  to  consider  the  application  and  of the 
deadline  for  the  submi~sion of  any  written  representations  the 
applicant  may  wish  to  make  in  accordance  with  Article  14  of 
Directive  75/319/EEC,  as  amended~  An  applicant  may  also  request 
an  oral  hearing  before  the  Committee~ If the  applicant  considers 
that  the  date  proposed  for  the  examination of  his  application  by  the 
Committee  does  not  provide  sufficient  time  for  the  preparation  of 
these  submissions  he  may  request  that  examination  of  the  application 
be  postponed  to  a  subsequent  meeting~  At  the  present  time  the  Committee 
usually  meets  once  every  two  to three  months~ 
~I~ -14  -
The  reasoned  opinion of  the  CPMP  is  exclusively  concerned  with 
the grounds  for  the  objections  put  forward  by  the  Member  States 
concerned~ The  opinion of the  Committee,  or  in  the  case of 
divergent  opinions,  the  opinions  of its  Members  are  immediately 
notified to  the  applicant  and  to  the  Member  States~ 
The  opinions  of  the  CPMP  do  not  replace  national  decisions~ 
However,  within  60  days  of  the  receipt  of the opinion,  the 
Member  States  concerned  must  decide  what  action to  take  on  the 
Committee's  opinion  and  inform  the  Committee  of that  decision~ 
The  Member  States  keep  the  Committee  informed  of the  action they 
are  taking  pursuant  to  an  opinion  until  such  time  as  a  definitive 
decision  is  adopted~ 
In  accordance  with  Article  214  of  the  EEC  Treaty  and  Article  19 
of its rules  of  procedure,  the deliberations of  the  CPMP  and  all 
documents  submitt~d are  confidential~ - 15  -
VII~  CONSIDERATION  OF  DIVERGENT  NATIONAL  DECISIONS 
When  a  proprietary  medicinal  product  has  been  authorized  for  use 
in one  or  more  Member  States,  and  has  been  refused  authorization 
or  suspended  or  withdrawn  from  the  market  in  one  or  more  of  the 
Member  States,  Article  11  of  Directive  75/319/EEC  as  amended 
empowers  a  Member  State or  the  Commission  to  refer  the  matter  to 
the  CPMP  for  its  opinion~ The  opinion of  the  Committee,  which 
must  be  given  within  60  days,  will  concern  the grounds  on  which 
the  marketing  authorizativn for  the  proprietary product  has  been 
suspended,  refused or  withdrawn,  and  the  Committee  may  invite 
the  person  responsible  for  marketing  the  product  to  explain  him-
self  in  writing  or  in  person  before  the  Committee~ - 16  -
VIII~  WRITTEN  REPRESENTATIONS  AND  ORAL  HEARINGS 
The  purpose of  written  representations  and  oral  hearings  is: 
- in  the  case  of  multi-state applications  for  MA  submitted 
pursuant  to  Article 9  of  Directive  75/319/EEC,  as  amended, 
to  enable  the  applicant  to  make  observations on  the  reasoned 
objections  put  forward  by  one  or  more  of the  Member  States 
concerned  by  the  application~ 
- in  the  case of matters  referred to  the  Committee  pursuant 
to  Article  11  of  Directive  75/319/EEC,  as  amended,  to enable, 
where  the  Committee  considers  it appropriate,  the  person 
responsible  for  marketing  the  product  to  make  observations 
on  the  grounds  for  the  refusal,  withdrawal  or  suspension of 
the  MA  given  by  one  or  more  Me.:.ber  States~ 
Applicants  using  the  multi-state  procedure  should  bear  in  mind 
that  oral  or  written  representations  are  made  to the  CPMP  as  a 
whole,  which  comprises  representatives  from  all  the  Member  States 
of  the  Community,  and  not  just to  the  countries  concerned  by  the 
application~ Although  the  authorities  which  are  not  directly  . 
concerned  by  the  application will  not  necessarily  have  seen  the 
complete  dossier,  they  will  have  seen  the  summaries 
of  the  dossier,  the  reasoned  objections of  the  Member  States 
which  are directly  concerned  by  the  application and  any  available 
assessment  reports~ 
In  order  to  enable  the  CPMP  to  concentrate  on  the  important  issues 
raised  concerning  the  acceptability of  a  proprietary product  on  grounds 
of quality,  safety  and  efficacy,  applicants  using  the  multi-state 
procedure  are  advised  to try to  resolve  any  minor  objections, 
particularly those  concerning  the  analytical  part  of the dossier, 
directly with  the  competent  authorities  concerned,  if possible 
before  the  date  on  which  the  Committee  will  consider  the  application~ - 17  -
Written  representations  should  be  sent  directly to all  the 
Members  of the  CPMP,  ~Jith  a  copy  to  the  Committee's  secretariat, 
whose  addresses  have  been  given  above,  and  should  reach  the 
members  at  Least  ten  days  before  the  meeting~ So  far  as  the 
Languages  in  which  representations  should  be  drafted  are  concerned, 
the guidelines  relating  to  the  submission  of  summaries  of the 
three  parts of the  dossier  should  be  followed  (see  the table 
on  P~ 13). It  should  therefore  be  noted  that  it will  usually 
be  necessary  to  provide  any  representations  in  English  and  French~ 
Any  written  representation  should  set  out  the  name  of the  proprietary 
product  concerned,  its  composition  in  terms  of  active principles 
and  the  name  and  address  of  the  person  responsible  for  marketing 
the  product~ 
Although  the  CPMP  does  not,  at  present,  wish  to  Lay  down  formal 
rules  of  procedure  governing  the  conduct  of oral  hearings,  the 
following  general  notes  are  offered  for  guidanceft  These  notes  are 
necessarily subject  to  revision  in  the  Light  of experience  and 
persons  contemplating  requesting  an  oral  hearing  are  advised  to 
seek  the  advice  of  the  Secretariat  at  an  early  stage~ 
i)  It  is  important  that  persons  preparing  for  and  attending 
hearings  bear  in  mind  that  the oral  proceedings  of  the  Committee 
are  multi-Lingual  and  that  simultaneous  technical  inter-
pretation during  the  hearing  will  be  necessary~  For  this 
reason  arguments  of  a  very  technical  or scientific  nature 
are  better  expressed  in  writingft 
ii)  Any  new  written  documents  to  be  used  in  conjunctiJn  with  a 
hearing  should  be  distributed to  the  Members  of  the  CPMP 
before  the  meeting"  In  addition the  Secretariat  will  require 
an  additional  10  copies  of  any  document  to  which  more  than 
passing  reference  is to  be  made  for  the  interpreters" 
iii)  Certain  visual  aids  may  be  made  available upon  request,  and 
persons  preparing  for  a  hearing  should discuss their  require-
ments  with  the  Secretariat~ Where  appropriate,  printed  copies 
of  the  material  used  should  be  made  available to  the  Secretariat 
in  advance~ - 18  -
iv)  Without  wishing  to  specify  a  formal  time  Limit,  the  CPMP  considers 
that  hearings  Lasting  more  than  one  hour,  including  both  the  presen-
tation by  the  company  and  questions  from  the  Committee,will  not 
usually  be  necessary.  Depending  on  the  issues  raised  in  the  reasoned 
objections  of  the  Member  States,  it  would  normally  be  appropriate 
for  between  one  and  four  persons  to  appear  on  behalf  of the  company 
concerned. 
v)  Persons  attending  hearings  should  notify  the  Secretariat  in  good 
time  of  the  Language  in  which  they  propose  to express  themselves 
so  that  arrangements  for  interpretation  can  be  made. 
vi)  Persons  attending  hearings  may  present  their  arguments  in  whatever 
manner  they  think  fit,  but  they  are  advised  not  to  spend  time  on 
arguments  which  are  not  relevant  to  the  reasoned objections  of  the 
Member  States to  an  application  forMA  or  to the  grounds  advanced 
by  Member  States  for  refusal,  suspension  or  withdrawal  of  a  MA. 
vii)  After  the  representatives  of  the  company  concerned  have  presented 
their  case,  the  chairman  will  allow  members  of  the  CPMP  to  put 
questions.  Thereafter,  the  representatives  will  be  asked  to  withdraw 
while  the  Committee  discusses  its opinion,  which  will  be  sent  in 
writing  to  the  company. - 19  -
IX.  LIST  OF  COMMUNITY  GUIDELINES  ON  THE  CONDUCT  OF  TESTS  AND  TRIALS  OF 
TESTS  AND  TRIALS  OF  PROPRIETARY  MEDICINAL  PRODUCTS  CAS  AT  1-7-85) 
A)  PHARMACO-TOXICOLOGICAL  TESTS 
1.  Repeated  dose  toxicity  (1) 
2.  Reproduction  studies  (1) 
3.  Carcinogenic  potential  (1) 
4.  Pharmacokinetics  and  Metabolic  Studies  in  the  Safety  Evaluation 
of  New  Drugs  in  Animals  (1) 
5.  Single  dose  toxicity  (2) 
6.  Testing  of  Medicinal  Products  for  their  Mutagenic  Potential  (2) 
B)  EFFICACY  STUDIES 
Notes 
1.  Fixed  Combination  Products  (1) 
2.  Cardiac  Glycosides  (2) 
3.  Clinical  Investigation  of  Oral  Contraceptives  (2) 
4.  User  Information  on  Oral  Contraceptives  (2) 
5.  Data  Sheets  for  Antimicrobial  Drugs  (2) 
6.  Clinical  Testing  Requirements  for  Drugs  for  Long  Term  Use  (2) 
7.  Non-Steroidal  Anti-Inflammatory  Compounds  for  the  Treatment  of 
Chronic  Disorders  (2) 
8.  Anti-Epileptic  I  Anticonvulsant  Drugs  (2) 
9.  Investigation of  Bioavailability  (2) 
10.  Clinical  Investigation of  Drugs  for  the  Treatment  of  Chronic 
Peripheral  Arterial  Diseases  (2) 
11.  Pharmacokinetic  Studies  in  Man  (2) 
12.  Anti-Anginal  Drugs  (3) 
13.  Corticosteroids  intended  for  Use  on  the  Skin  (3) 
(1)  Adopted  by  the  Council  and  included  in  Council  Recommendation  83/571/EEC 
of  26  October  1983  concerning  tests  relating  to  the  placing  on  the  market 
of  proprietary  medicinal  products  (O.J.  L 332/11  of  28.11.83). 
(2) Accepted  by  the  Committee  for  Proprietary  Medicinal  Products  and  included 
in  the  Commission  Proposal  of  25  September  1984  for  a  Council  Recommendation 
concerning  tests  relating  to  the  placing  on  the  market  of  proprietary 
medicinal  products  (COM(84)437  final,  O.J.  C 293  of  5.11.84). 
(3)  Accepted  by  the  Committee  for  Proprietary Medicinal  Products  and  included 
in  the  modifications  to  the  Commission  Proposals  of  25  September  1984 
submitted  to  the  Council  on  4  March  1986  CCOM(86)117). 
/ - 21  -
ANNEX  I 
PRESENTATION  OF  APPLICATIONS  FOR  MARKETING  AUTHORIZATION 
Part  I:  General  information 
1.  Name  of  the  proprietary medicinal  product 
2.  Pharmaceutical  form  (including  route  of administration),  strength  and 
presentation 
3.  Name  or  business  name  and  address  of  the  applicant 
4a.  Name  and  address  of  the  company  responsible  for  the  marketing  of  the 
product 
4b.  Name(s)  and  address(es)  of  the manufacturer(s)  involved  in  the 
manufacturing  process  (including  a  description  of  the  steps  they  perform) 
5.  Name  and  address  of  importer  (where  applicable) 
6.  Name  and  address  of distributor  <where  applicable) 
7.  Number  of  volumes  supplied  in  support  of  the application.  In  case of 
a  multi-State application differences  from  the  file  on  the  basis  of 
which  the marketing  authorization  in  the  Member  State of origin was 
granted  should  be  indicated 
8.  Date  and  signature of  the applicant. 
1.  Name  of  the  proprietary medicinal  product 
2.  Qualitative and  quantitative  composition  in  terms  of  the  active 
ingredients and  constituents of  the  excipient,  knowledge  of  which  is 
essential  for  proper administration  of  the  medicinal  product;  the 
international  non-proprietary  names  recommended  by  the  World  Health 
Organization  shall  be  used,  where  such  names  exist,  or  failing  this, 
the  usual  common  name  or  chemical  description 
3.  Pharmaceutical  form  (including  route  of administration) 
4.  Pharmacological  properties and,  in  so  far  as  this  information  is 
useful  for  therapeutic  purposes,  pharmacokinetic  particulars. 
. I. 5.  Clinical  particulars: 
5.1.  therapeutic  indications 
5.2.  contra  indications 
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5.3.  undesirable  effects  (frequence  and  seriousness) 
5.4.  special  precautions  for  use 
5.5.  use  during  pregnancy  and  lactation 
5.6.  interaction with  other  medicaments  and  other  forms  of  interaction 
5.7.  posology  and  method  of administration  for  adults and,  where 
necessary,  for  children  (and/or  the  elderly) 
5.8.  overdose  (symptoms,  emergency  procedure,  antidotes) 
5.9.  special  warnings 
5.10.  effects  on  ability to  drive  and  use  machines. 
6.  Pharmaceutical  particulars: 
6.1.  incompatibilities  (major) 
6.2.  shelf  life,  when  necessary after  reconstitution of  the  product 
or  when  the  container  is  opened  for  the  first  time 
6.3.  special  precautions  for  storage 
6.4.  nature  and  contents of  container 
6.5.  name,  or  style and  permanent  address  or  registered  place of 
business  of  the  holder  of  the  marketing  authorization. 
For  multi-State applications:  where  the  information  given  above  differs 
from  the  text  approved  by  the  Member  State  from  which  the  application 
originates,  the  divergences  should  be  marked  (e.g.  with  an  asterix). 
1.  Chemical  and  pharmaceutical  documentation 
2.  Toxicological  and  pharmacological  documentation 
3.  Clinical  documentation. 
. I. - 23  -
Part  II:  Chemical  and  pharmaceutical  documentation 
Part  II  A:  £QffiQQ2i!iQD 
1.  Composition  of  the  proprietary medicinal  product 
Names  of  constituents  Quantity  Reference  to  standards 
Active  constituents 
Other  constituents 
2.  Container  (brief description) 
3.  Clinical trial  formula(e) 
4.  Development  pharmaceutics 
Explanation with  regard  to  the  choice  of  the  composition,  constituents 
and  container,  supported,  if necessary,  by  data  on  development 
pharmaceutics.  The  overage,  with  justification thereof,  should  be 
stated. 
1.  Manufacturing  formula  (including  details of  batch  size) 
2.  Manufacturing  process  (including  in-process  control  and  the  pharmaceutical 
assembly  process 
3.  Validation of  the  process  (experimental  data  showing  that  the 
manufacturing  process,  using  starting materials  of  the  stated quality and 
the  types  of manufacturing  equipment  specified,  is  a  suitable one  and  will 
consistently yield a  product  of  the  desired quality). 
1.1.  Active  constituents  (specifications  and  routine  tests) 
1.1.1.  Active  constituents  described  in  a  pharmacopoeia 
1.1.2.  Active  constituents  not  described  in  a  pharmacopoeia 
- Appearance 
- Identity tests 
- Physical  tests 
- Chemical  tests 
- Other  tests 
- Assay(s) 
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1.2.  Active  constituents  (scientific  data) 
1.2.1.  Nomenclature 
- International  non-proprietary  name  (INN) 
- Chemical  name 
- Other  name(s) 
- Laboratory  code 
1.2.2.  Description 
- Physical  form 
- Structural  formula 
- Molecular  formula 
- Molecular  weight 
1.2.3.  Manufacture 
- Name(s)  and  addressees)  of  the  manufacturing  source(s) 
- Synthetic  route 
- Description of  process 
- Solvents  and  reagents 
- Catalysts 
- Final  purification 
1.2.4.  Quality  control  during  synthesis 
- Starting materials 
- Intermediates  tested 
1.2.5.  Development  chemistry 
- Evidence  of  chemical  structure  (synthetic  route,  key 
intermediates,  elemental  analysis,  mass  spectrum,  NMR, 
IR,  UV,  other) 
- Potential  isomerism 
-Physico-chemical  characterisation  (solubility,  physical 
characteristics,  polymorphism,  pKa  and  pH  values,  other) 
- Analytical  development 
1.2.6.  Impurities 
- Potential  impurities  originating  from  the  route  of  synthesis 
- Potential  impurities  originating  from  degradation  as 
evidenced  by  exposing  the material  to  stress  conditions 
Cheat,  Light,  acids,  bases  etc.) 
-Analytical methods  and  their  Limits  of  detection 
- Impurities  found 
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1.2.7.  Batch  analysis 
- Batches  tested  (date  of manufacture,  place  of  manufacture,  batch 
size,  and  use  of  batches) 
- Results  of tests 
- Reference  Standard  (results  of tests) 
2.1.  Other  constituents  (specifications and  routine  tests) 
2.1.1.  Constituents  described  in  a  pharmacopoeia 
2.1.2.  Constituents  not  described  in  a  pharmacopoeia 
- Appearance 
- Identity tests 
- Physical  tests 
- Other  tests 
- Assay(s) 
2.2.  Other  constituents:  data,  when  necessary,  e.g.  excipients  used  for 
the  first  time  in  medicinal  products  (see  II  C.1.2.) 
3.  Packaging  material 
-Type of material 
- Construction 
- Quality  specifications  <routine  tests) 
-Development/validation studies. 
A distinction  should  be  made  between  in-process  controls  (part  II  B) 
and  control  tests on  intermediate  products. 
1.  General  characteristics,  other  quality  control  tests  required  by  the 
nature  of  the  product; 
- description  and  general  characteristics  (dimension,  shape,  colour, 
odour  and  distinguishing  features) 
2.  Identification and  quantitative  determination  of  the active  principle 
or  principles,  other  quality  control  tests,  with  a  description of  the 
methods  employed  (including,  if necessary,  and  depending  on  the 
nature  of  the  product,  biological  and  microbiological  methods) 
- Identification tests 
- Quantitative determination  of active  ingredients 
- Pharmaceutical/technical  tests e.g.  dissolution  rate 
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- Identification of  colouring  matter 
- Determination  of  antimicrobial  or  chemical  preservatives 
3.  Validation of  the  methods  employed 
4.  Batch  analysis 
Part  II  F:  ~!~~ili!~ 
1.  Proposed  shelf  Life  (depending  on  the  type  of  container  and  storage 
precautions) 
When  necessary  the  shelf  Life after  reconstitution of  the  product  or 
when  the  container  is  opened  for  the  first  time. 
2.  Information  concerning  stability,  including  physical  stability,  of 
the  finished  product: 
- Number  of batches  tested 
- Storage  conditions 
- Methods  employed 
- Description  of  containers 
- Analytical  methods  (if different  to  those  in  Part  II  E)  and 
specifications 
- Results  of  tests and  interpretation 
3.  Stability tests on  active  constituent(s) 
- Number  of batches  tested 
- Storage  conditions 
- Methods  employed 
- Description  of  containers 
- Analytical  methods 
- Results  of tests and  interpretation 
4.  Validation of  the  methods  employed 
This  part  is  intended  for  information  not  covered  by  any  of  the  previous 
parts  e.g.  the  analytical  tests  used  in  studies  concerning  metabolism 
and  bioavailability. 
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Part  III:  Toxicological  and  pharmacological  documentation 
If  use  is  made  of a  List  of  published  references  pursuant  to  point  8 
of  the  second  paragraph  of  Article  4  of  Council  Directive 65/65/EEC 
(OJ  No  22  of 9  February  1965),  the  expert  must  show  that  this  is 
justified. 
The  following  information  must  be  provided  in  respect  of 
1 •  Animals  used  (species,  strain,  sex,  age,  weight  etc.) 
2.  Product  used  (number  of  the  batch,  quality  etc.) 
3.  Experimental  conditions  including  diet  and  husbandry 
4.  Results. 
Part  III  A:  ~£~!~_!Q~i£i!~ 
Part  III  8:  I2~i£i!~-~i!b_r~Q~~!~9-~9~ioi~!r~!i2o 
8.1.  Subacute  toxicity trials 
8.2.  Chronic  toxicity trials 
Part  III  C:  £Q~!~l_!Q~i£i!~-~QQ_f~r!ili!~-~!~Qi~~ 
each  test: 
C.1.  Tests  for  teratogenicity  (dosing  during  period  of  organogenesis) 
C.2.  Pre- and  postnatal  dosing  of  the  mother  to  demonstrate  effects  on 
Late  pregnancy,  parturition and  lactation,  behavioural  and 
developmental  effects  on  the  offspring 
C.3.  Fertility studies 
Part  III  F:  Eb~r~~fQQ~Q~~i£~ 
F.1.  Actions  relevant  to  the  proposed  therapeutic  uses 
F.2.  Other  actions  investigated 
F.3.  Interactions 
Part  III  G:  Eb~r~~fQ~iD~!i£~ 
G.1.  Absorption 
G.2.  Distribution  in  normal  and  pregnant  animals 
G. 3.  MetaboLism 
G.4.  Excretion  of  the  parent  compound  and  its metabolites 
Part  III  Q:  Q!b~r_iDlQ£~~!i2D 
This  part  is  intended  for  possible  information  not  covered  by  any  of  the 
previous  parts. 
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Part  IV:  Clinical  documentation 
If  use  is  made  of  a  List  of  published  references  pursuant  to  point  8  of 
the  second  paragraph  of  Article  4  of  Council  Directive  65/65/EEC 
(OJ  No  22  of  9  February  1965),  the  expert  must  show  that  this  is  justified. 
Part  IV  A:  ~~~~Q_QQ2I~~f21Q9~ 
<where  appropriate  in  healthy  volunteers,  patients and  special  risk  groups) 
A.1.  Pharmacodynamics 
1.1.  Pharmacological  actions 
1.2.  Pharmacodynamic  mechanisms  underlying  the  therapeutic  effects 
A.2.  Pharmacokinetics 
2.1.  Absorption,  including bioavailability 
2.2.  Distribution  and  protein binding 
2.3.  Metabolism 
2.4.  Excretion 
2.5.  Kinetic  interactions 
Part  IV  8:  f1iQi£~1_9Q£~~~~!~!i2Q 
8.1.  Individual  trials and  summaries  thereof  (efficacy and  tolerance) 
<including  unfinished  studies) 
1.1.  Detail  research  design  (protocol) 
1.2.  Final  or  intermediate  report  including  statistical and  medical 
evaluation  and,  where  necessary,  individual  patient  data. 
Submission  of  the  raw  data  is  necessary  only  on  request. 
1.3.  Summary  of  each  trial 
1.4.  Detailed clinical  and  Laboratory  monitoring  results which  should 
be  capable  of  easy  relation  to  individual  patients. 
8.2.  Postmarketing  experience 
2.1.  Adverse  reaction monitoring  and  reports 
2.2.  Number  of  patients  exposed 
8.3.  Published and  unpublished  experience  (other  than  8.1.) 
. I. 8.4.  Conclusions 
4.1.  Therapeutic  effect 
4.2.  Adverse  reactions 
4.3.  Interactions 
4.4.  Drug  dependence 
4.5.  Car  driving 
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4.6.  Pregnancy,  breast  feeding,  elderly  people,  children,  special 
pathological  conditions  <e.g.  impairment  of  Liver  and  kidney 
functions) 
4.7.  Dosage  (dosage  interval,  duration  of  therapy) 
4.8.  Overdosage  and  intoxication 
Part  IV  Q:  Other  information  -----------------
This  part  is  intended  for  information  not  covered  by  any  of  the  previous 
parts. 
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Part  V:  Special  particulars 
Part  v A:  QQ~~g~_1Qr~ 
1.  Packaging 
2.  Label 
3.  Package  insert 
Part  V B:  ~~~Qi~~ 
(where  applicable;  see  page  11  of  the  Notice  to  Applicants) 
List  and  description of  samples  accompanying  the  application. 
Part  V C:  Manufacturers  authorization(s)  ------------------------------
Part  V D:  ~~[~~!iD9-~~!h2ri~~!i2Di~~ 
1.  Marketing  authorization  from  Member  State of origin and  summary  of 
product  characteristics approved  by  it 
2.  Copies  of  marketing  authorizations  granted by  other  Member  States 
3.  Third  countries  in which  a  marketing  authorization  is granted. - 31  -
ANNEX  II 
PREPARATION  OF  THE  EXPERTS.REPORTS  OE  APPLICANT 
IA  INTRODUCTION 
In  accordance  with  Directive  75/319/EEC,  article 2,  the  pharmaceutical, 
pharmaco-toxicological  and  clinical  parts  of  the  complete  dossier 
should  each  include  an  expert  reportA  It  is emphasized  that  well 
prepared  expert  reports greatly facilitate  the  task  of  the  competent 
authorities  in  evaluating  the  dossier  and  contribute to  the  speedy 
processing  of  applicationsA  For  these  reasons  particular  care  should 
be  taken  in  the  preparation of  the  expert  reportsA 
In  these  notes  for  guidance  the  structure of  the  expert  reports  is 
described  and  some  indications  are  given  with  regard  to their 
content A 
The  experts  selected  by  the  applicant  to  draw  up  the  report  should  be 
able to  present  a  full  and  accurate  summary  of  each  part  of  the dossier 
in  accordance  with  this  explanatory  note.  It  is not,  however,  necessary 
for  them  to  have  been  personally  involved  in  the  performance  of  the 
tests they  describe. - 32  -
II. GENERAL  CONSIDERATIONS 
1.  In  order  to  produce  an  expert  report  it is essential to  consult 
'~he Rules  Governing  Medicaments  in  The  European  Community'' 
(see  page  4  for  bibliographical data). 
The  structure  proposed  in this  Annex  follows  the order  of  presentation 
for  applications  for  authorizations to market  proprietary  medicinal 
products  described  in  Annex  I. 
2.  The  expert  report  should  consist  of  a  concise  and  comprehensive 
synopsis,  briefly  but  exhaustively describing  the  quality of  the 
products  and  the  investigations on  animals  and  human  beings.  It 
should  include  a  critical  comment  of  the  expert.  It  must  be  worded 
so  as  to  enable  the  reader  to  obtain  a  good  understanding  of  the 
properties,  the  quality,  the  proposed  control  methods,  the  safety, 
the  efficacy,  the  advantages  and  the disadvantages  of  the  product. 
3~ The  facts  and  data  mentioned  in  the  report  should  refer  to  the 
relevant  place or  page  in  the  documentation~ 
4~  ALL  important  data  should  be  summarized~ The  presentation  in  tabular 
or  graphic  form  is often  advantageous~  Some  examples  of  tables  are 
annexed,  where  appropriate  other  tables  may  be  used~ 
5~  Each  application  shall  contain  three  expert  reports,  covering  the 
three  parts of  the  file: 
a~  Chemical  and  pharmaceutical  documentation  (normally  Less  than 
25  pages) 
b~ Toxicological  and  pharmacological  documentation  (normally  Less 
than  25  pages) 
c.  Clinical  documentation. 
6~  An  expert  report  should  bear  the  signature of  the expert(s)  and  the 
place  and  date  of  its  issue~ 
Attached  to the  report  there  should  be  brief  information  on  the 
expert(s):  their  name(s),  educational  background  training  and 
occupation-
The  professional  relationship of  the  expert  to the  applicant  should 
be  declared. - 33  -
III  EXPERT  REPORT  ON  THE  CHEMICAL  AND  PHARMACEUTICAL  DOCUMENTATION 
The  expert  report  should  consist of  the  following  sections: 
1.  Composition 
2.  Method  of  preparation 
3.  Control of starting materials 
a.  Active constituents 
b.  Other  constituents 
c.  Packaging  material 
4.  Control  tests on  intermediate  products 
5.  Control  tests on  the  finished  product 
6.  Stability 
7.  Miscellaneous 
B.  Conclusion 
9.  Reference  list 
10.  Information  on  the  expert(s) 
Examples  of  sui table  forms  which  may  be  used,  if  desired,  by 
th~ expert  as  a  format  for  the  relevant  expert  work  are  atta-
ched  (  Pages47- 61).  Use  of  the  forms  facilitates  a  clear  and 
well-ordered  presentation  of  the  data.  Individual  sections  of 
the  forms  can  be  adapted  as  required  by  expanding  or  contrac-
ting, them.  Page  references  on  the  forms  should  be  made  to  the 
ap~ropriate  page  and  column  of  the  full  dossier.  The  comments 
column  should  be  left blank  by  the  applicant. 
1.  Composition  {part  II  A) 
The  complete  qualitative  and  quantitative  composition  of  the 
finished  product  must  be  given  with  a  brief description of  the 
container(s)  in  which  it will  be  put  on  the  market. 
If  the  composition  used  in  clinical  trials  differs  from  the 
finally  chosen  composition  the  differences  should  be  indicated 
and  their  significance discussed. 
~~~~!~e~~~~-e~~~~~~~~~!~! 
The  essential  elements  of  the  development  work  undertaken  to 
produce  the  final  formulation  is  to  be  summarized,  together 
with  any  relevant  analytical data  on  raw  materials  and  the  fi-
nished  products.  This  summary  should  explain  the  choice  of 
constituents  and  container(s). 
2.  Method  of preparation  (part  II  B) 
The  method  of preparation of  the  finished  product,  th~  in-pro-- 34  -
cess  controls  and  the  particular  manufacturing  precautions 
should  be  summarized  and  evaluated. 
An·  opinion  should  be  given  on  the  process  validation  studies. 
The  expert  should  indicate  how  the  process  validation  data 
guarantees  the  production  of  a  medicinal  product  of consistent 
quality. 
3.  Control of  starting materials  (part  II  C) 
a.  Active  constituents 
o.  Other  constituents 
c.  Packaging  material 
An  opinion  on  the  analytical  testing  of  starting  materials 
which  are  described  in  a  recognised  pharmacopoeia  is  required 
only  if  additional  tests  have  been  carried  out.  If  the  method 
of  synthesis of  a  starting material  gives  reason  to  expect  im-
purities  in  it  which  are  not  taken  into  account  in  the  mono-
graph  published  in  the  pharmacopoeia,  the  analytical  results 
should  show  that  no  impurities  have  been  introduced  in  manu-
facture,  storage  etc.  which  are  not  covered  by  these  additio-
nal  tests. 
If  the  starting  materials (including  container  materials)  are 
tested  in  accordance  with  test specifications  developed  on  the 
pattern  of  a  pharmacopoeia  monograph,  the  expert  should  indi-
cate  how  certain  the  identity of  the  material  is.  For  the  pu-
rity  test  it  must  be  evident  from  the  opinion  that  no  impuri-
ties  resulting,  for  example,  from  manufacturing  methods  or 
storage  are  present  which  are  not  covered  by  the  purity  test. 
The  expert  should  summarize  the  data  on  validation of  the  ana-
lytical  methods  to  show  their  sensitivity,  precision,  lineari-
ty  etc.  The  specificity of  the  assay  methods  for  starting  ma-
terials must  be  described. 
For  new  active principles  the  expert  should  summarize  the  stu-
dies  showing  their  chemical  and  physical  properties  (including 
comment  on  the  significance of  these  properties  in  relation  to 
the  bioavailability  and  pharmacokinetic  properties of  the  pre-
paration. 
4.  Control  tests on  intermediate  products  (part  II  D) 
5.  Control  tests on  the  finished  product  (part  II  E) 
Control  methods  for  intermediate  products  and  the  finished 
product  are  to  be  assessed  in  each  case  even  if  they  are,  or 
are  derived  from,  pharmacopoeia  methods. 
The  expert  should  summarize  the  data  on  validation of analyti-- 35  -
cal  methods.  He  should  comment  on  how  the  tests  proposed  gua-
rantee  that  the  finished  product  made  on  a  production  scale 
does  not  differ  in  respect of  assay,  physical  and  organoleptic 
~ 
properties,  composition  or  pharmaceutical  properties  from  the 
scale  of  manufacture  described  in  the  application  for  marke-
ting  authorisation. 
6.  Stability  (part  II  F) 
For  .new  compounds  the  possible  degradation  and  degradation 
products  should  be  discussed" 
It  should  be  indica  ted  whether  deg r ad at ion  can  develop  du-
ring  storage  or  manufacture  of  the  finished  product,  how  tes-
ting  was  carried  out,  with  what  certainty  the  degradation 
products  were  covered  by  the  tests,  what  detection  limits  are 
to  expected  from  the  proposed  methods.  The  shelf-life  should 
be  stated  together  with  proposals  for  any  storage  warnings. 
7.  Miscellaneous 
Under  this  heading  other  relevant  information  is  described, 
which  is not  covered  by  the  previous  headings. 
8.  Conclusion 
The  conclusion  should  show  in  particular  whether  the  proprie-
tary  medicirial  product  is  of  the  appropriate  quality  and 
whether  the  proposed  control  methods  correspond  to  the  state 
of  the  art  and  are  an  appropriate  means  of  assessing  quality. 
9.  Reference  list 
References  should  be  complete  and  formulated  in  accordance 
with  internationally accepted  standards,  and  include  all lite-
rature cited. 
The  references  must  be  numbered  and  each  reference  should  be 
easily located  in  the  application  file  in  question. 
10.  Information  on  the  expert(s) - 36  -
IV  EXPERT  REPORT  ON  THE  TOXICOLOGICAL  AND  PHARMACOLOGICAL  DOCU-
MENTATION 
The  expert  report  should  consist of  the  following  sections: 
1.  Introduction 
2.  Toxicity 
2a.  Acute  toxicity 
2b.  Toxicity with  repeated~administration 
2c.  Foetal  toxicity and  fertility studies 
2d.  Mutagenic  potential 
2e.  Carcinogenic  potential 
3.  Pharmacodynamics 
4.  Pharmacokinetics 
5.  Miscellaneous 
6.  Conclusion 
7.  Reference  list 
8.  Information  on  the  expert ( s) 
1.  Introduction 
2.  Toxicity  {part  III  A  - {III  E) 
For  all  toxicological  tests  the  reasons  for  the  selection  of 
species,  dose,  application,  duration  of  treatment/experiment 
and  the  number  of  animals  used  should  be  justified,  having 
regard  to  pharmacokinetic/metabolic  data,  and  to  pharmacody-
namic  effects  relating  to  the  toxicological  studies,  and  to 
the  relationship  between  the  animal  species  used  and  between 
animal  and  man. 
Toxicological  studies  relating  to  the  same  problem  should  be 
documented  together  and  state  the  value  of  their  extrapolation 
to  man ..  If other  experimental  models  than  whole  ani-
mals  are  used  their  validity  should  be  established. 
Consequences  regarding  special  populations  at  risk,  and  need 
for  further  studies  should  be  stated  and  judged. I  , 
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2~A~Acute toxicity  (part  III  A) 
The  acute  toxicity  tests  should  be  summarized  (tabulated)  for 
each  species  and  route  of  administration.  (An  example  of  a 
tabular  presentation  is  given  in  the  annex.)  Toxic  symptoms 
should  be  described  as  well  as  any  other  relevant  information 
. 
e.g.  cause  of death.  Any  species  or  sex differences  should  be 
at,  ted. 
An  evaluation  should  be  given of: 
- local  damage  at  the  site of  administration  and  organ  damage 
l 
- time  course of  behavioural  modification  and  death 
- interactions  with  other  ingredients  of  the  proprietary  me-
dicinal  product  (fixed  combinations). 
Dose-response  relationships  should  be  evaluated.  Precise  in-
formation  on  the  lethal  dose-response  relationships 
is not  required  if  the  maximum  non-lethal  dose  and/or  the  mi-
nimum  lethal dose  can  be  judged. 
2~B~Toxicity with  repeated  administration  (part  III  B) 
Data  should  be  summarized  for  each  species,  specifying  the 
duration  of  the  test  and  the  route  of  administration.  For 
each  investigation  the  dosage  is  to  be  stated  as  well  as  the 
numper  of  animals  per  dose  level,  the  sex  of  the  animals  and 
now  frequently  the  drugs  have  been  given.  (An  example  of  a 
tabular  presentation  is given  in  the  annex.)  The  dosages  cho-
sen  should  be  discussed  and  justified,  giving  special  regard 
to  the  relationship  between  duration of  study  and  dose  (phar-
m  a co k in  e tics) . 
The  parameters  studied,  including  laboratory  tests  and  patho-
logical  investigations,  should  be  stated,  and  the  results 
that  are  relevant  to  the  assessment  should  be  summarized. 
The  evaluation  of  toxic  effects  should  consider  the  time  of 
appearance,  dose  dependency,  their  reversibility  (irreversi-
bility),  and  their  possible  causes. 
2  ~CRoetal toxicity and  fertility studies  (part  III  C) 
Investigations  into  teratogenic  and  other  embryotoxic  ef-
fects,  peri- and  postnatal  toxicity,  and  fertility  should  be 
summarized  for  each  species  and  route  of  administration.  For 
each  study  the  dosage,  the  number  of  animals  per  dose  and  the 
period  of  administration  in  relation  to  gestation  should  be 
specified.  The  parameters  studied  as  well  as  the  methods  used - 38  -
to  examine  foetuses  should  also  be  described.  Maternal  and 
paternal  reactions  should  be  reported,  as  well  as  the  drug's 
effect on  the  course  of pregnancy,  the  foetus  and  the  young. 
The  risk  involved  when  using  the  drug  in  connection  with 
pregnancy  in  man  should  be  discussed. 
2 "D Mutagenic  potential  (part  III  D) 
All  mutagenicity  studies  should  be  summarized.  The  mutagenic 
potential  must  be  discussed  taking  into  account  the  chemical 
structure  of  the  compound,  the  mode  of  action,  relationship 
to  known  mutagens,  the  pharmacokinetics  in  man. 
2 "E  Carcinogenic potential  (part  III  E) 
Data  from  carcinogenicity studies must  be  summarized,  stating 
animal  species,  dosages,  route  of  administration,  length  of 
test,  number  and  sex  of  animals.  The  results  must  be  statis-
tically  analysed.  If  tumours  are  observed,  their  type,  fre-
quency  and  time  of  occurence  must  be  summarized,  and  their 
possible  cause  should  be  discussed. 
The  estimation of  the  carcinogenic  potential of  the  drug  must 
take  into  account  the  chemical  structure,  relationship  to 
known  carcinogens,  mode  of  actions  (if possible),  mutagenici-
ty  ~tudies and  carcinogenicity  studies  in  animals. 
If  epidemiological  data,  or  data  from  clinical  trials  are 
available,  these  should  be  included  in  the  discussion. 
The  estimated  carcinogenic  risk  for  man  should  be  discussed. 
3.  Pharmacodynamics  (part  III  F) 
Studies  of  the  primary  pharmacological  effects  and  rrode  of 
actions  forming  the  basis  for  the  drug  recommended  use  should 
be  summarised,  with  particular  reference  to  quantitative  as-
pects.  The  relation  between  dose  and  effect  should  be  descri-
bed. 
Studies  of  secondary  pharmacological  effects of  the  drug  must 
also  be  reported. 
The  data  should  be  aiscussed  with  regard  to: 
- desired  effects: 
species  u~ed  (strain,  sex),  rearing  methods,  anesthesia  of 
experimental  animals,  etc.; 
- mode  of  action  (if possible): 
systemic  actions,  actions  on  cells  and  subcellular  structu-
res  and  biochemically detected  actions; - 39  -
- safety: 
indications of  undesirable  actions,  e.g.  interactions,  to-
lerance  and  possible acute  poisoning. 
4.  Pharmacokinetics  (part  III  G) 
Studies  of  absorption,  distribution,  metabolism  and 
excretion  should  be  summarized,  with  reference  to  any  species 
differences  for  the  relevant  routes  of  administration  and  do-
sage  forms.  A  comparison  to  human  kinetics  should  be  made. 
The  relevance  for  the ,toxicological  studies  should  be  discus-
sed.  Possible  kinetic  interactions  should  also  be  discussed. 
The  choice  of  pharmacokinetic  models  and  calculations  for 
pharmacokinetic constants  should  be  explained.  When  statisti-
cal  calculations  are  included  the  methods  used  and  reasons 
for  their  use  should  be  stated.  Bioavailability data  should  be 
summarized  and  discussed" 
5.  Miscellaneous 
This  section  is  intended  for  summaries  of  studies  not  covered 
by  any  of  the  previous  headings  e.g.  tissue-irritant effects, 
sensitization,  risk  of  addiction  or  dependency,  specific  to-
xic effects or  comparison  of different  dosage  forms. 
6.  Conclusion 
The  expert  should  state  what  conclusions  can  be  drawn  from 
the  results of  the  tests.  The  pharmacological  and  toxicologi-
cal observations  should  be  discussed  in  the  light of  relevant 
scientific  literature,  paying  particular  attention  to  the 
drug's  characteristics  in  comparison  with  those  of  any  rela-
ted  already  known  drugs.  The  pharmacological  and  toxicologi-
cal  data  presented  in  this. section  should  be  evaluated  where 
possible  in 'relation  to  the  proposed  clinical  use  of  the  com- 1 
pound.  Both  efficacy  and  risk  aspects  derived  from  the  pre-
clinical documentation  should  be  considered. 
Points  to  be  included  in  the  discussion: 
- choice of  doses  or  effective concentrations; 
-plausibility  in  the  selection  of  species,  e.g.  by  kinetics 
and  metabolism; 
- assessment  of  a  possible  cumulation,  tachyphylaxis,  tole-
rance  development  or  withdrawal  symptoms; 
- assessment  of  pharmacological  data  for  treatment  of  acute 
poisoning,  e.g.  antidotes or  other  specific measures; jl 
l 
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- formal  compilation  of  results,  especially  a  critical 
examination of  the  statistical methods  used1 
- shortcomings  existing  at  the  beginning  of  testing,  in  the 
performance  of  the  tests or  in  the  conclusions; 
- risk criteria, i.e.  indication of narrow  therapeutic  range; 
- results of  animal  experiments  related  to clinical trials; 
- animal  husbandry  and  standards of  good  laboratory practice 
7.  Reference  list 
References  should  be, complete  and  formulated  in  accordance 
with  internationally  accepted  standards,  and  include  all  li-
terature cited. 
The  references  must  be  numbered  and  each  reference  should  be 
easily  located  in  the  application  file  in  question. 
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V  EXPERT  REPORT  ON  THE  CLINICAL  DOCUMENTATION 
The  expert  report  should  consist of  the  following  sections: 
1 •  In trod  uc t ion 
2.  Human  pharmacology 
3.  Clinical documentation 
4.  Miscellaneous 
5.  Conclusion 
6.  Reference  list 
7.  Information  on  the  expert(s) 
1.  Introduction 
2.  Human  pharmacology  (part  IV  A) 
2.1.  Pharmacodynamics 
The  effect  and  mode,  if  possible,  of  action  of  the  product, 
'  relevant  to  the  indications  for  which  it  is  intended,  must 
be  described.  The  duration  of  action  and  the  relationships 
between  the  dose,  plasma  concentration,  effect  and  time 
should  be  elucidated.  Effects  on  other  organ  systems  should 
also  be  included,  as  well  as  tolerability  in  general. 
The  documentation  should  cover  i.a.: 
- definition of healthy  volunteers  and  patients 
- number  of  subjects 
- age  groups 
- methods  of  registration and  evaluation 
- mode  of  action{s) 
-desired effect(s) 
-,effect (s)  of different organ  systems 
- possible  side effects 
- dose-response  relationship 
- time-effect  relationship 
- dose-plasma  concentration  relationship 
optimal dose  and  dose  regimens 
- statistical methods - 42  -
2.2.  Pharmacokinetics 
A  summary  of  the  pharmacokinetics  profile  of  the  drug,  as 
well  as  adequate  ~urves and  tables  must  be  presented. 
The  documentation  should  cover  i.a.: 
- aims  of  the  investigation 
- methods 
- number  of  subjects 
- age-groups 
- healthy  volunteers or  patients 
- design  of  trials 
- dosage,  modes  of  administration 
- intersubject variability 
The  report  should  comprise  inter  alia  :  rate  and  extent  of  absorp-
.tion,  distribution,  protein  binding,  metabolism,  in-
cluding  any  results  on  possible  genetic  fX>lymorphism,  oc-
curence  of  active  and  inactive metabolites,  if possible,  and 
elimination  characteristics  (e.q.  total  oody  clearance  and 
elimination  halflife)  and  excretion  pathways  including  the 
metabolites.  When  relevant,  information  should  be  included 
concerning  old  age,  children  and  patients  with  impaired  re-
nal  and/or  hepatic  function,  and  other  riel<  groups.  For 
druqs  intended  for  chronic  use  information  on  steady  state 
kinetics  should  be  given.  Kinetic  interactions  should  be 
elucidated  if  suspected.  Differences  between  human  and  ani-
mal  pharmacokinetic  features  should  be  emphasized. 
2.3.  Interactions 
It  should  be  stated  whether  interactions  exist  betwee"'l.  the 
drug  in  question  and  relevant other  drugs  likely  to  be  coad-
m  in is te red. 
3.  Clinical documentation  (part  IV  B) 
3.1.  Therapeutic  effect 
The  main  purpose  of  the  clinical documentation  is  to  demon-
strate  the  therapeutic  effect  of  the  proprietary  medicinal 
product,  where  appropriate,  in  comparison  with  existing  therapy~ The  expert 
report  should  reflect  this.  The  data  and  the  qualified  eva-
luation  should  give  a  clear  picture of  the  therapeutic  char-
acteristics,  efficacy  and  tolerance. 
A  tabular  pr esen tat  ion  of  all  clinical  trials  should  be 
given.  This  should  contain  the  main  characteristics  of  the - 43  -
trials,  such  as  the  title of  the  study  and  the  country  in 
which  it  was  carried out,  the type,  the  number  of  patients, 
the  dose  regimen  and  route  of  administration,  the  duration 
of  treatment,  the  diagnosis  and  the  reference  drug,  if  any 
(An  example  is  given  in  the  annex.). 
The  most  important  trials  should  be  summarized  individually 
CAn  example  for  a  tabular  presentation  is  given  in  the  an-
nex.). 
Therefore  special  emphasize  should  be  given  in  the  presenta-
tion  of  those  trials  (phase  II)  which  give  unequivocal  evi-
dence  of  the  efficacy  and  provide  justification of  the  pro-
posed  therapeutic  dosage  regimens.  Any  relationship  between 
efficacy  and  dosage  and/or  duration  of  treatment  and/or  par-
ticular patient  populations  should  be  described.  If  the 
treatment  with  the  product  could  be  improved  through  plasma 
concentration  monitoring,  documentation  for  e.g.  an  optimal 
therapeutic  plasma  range  should  be  included. 
If different  formulations  and/or  different  routes  of  admi-
nistration  have  been  used  the  tables  should  show  the  number 
of  patients  subjected  to  each  formulation  and  route  of  admi-
nistration. 
The  results  should  be  summarized  (therapeutic  results,  ob-
served  side effects,  observed  interactions ect.). 
For  each  indication  the  evidence  for  efficacy at  the  dosage 
proposed  should  be  given.  The  objective  and  subjective  cri-
teria  for  efficacy  should  be  specified  (e.g.  reduction  of 
blood  pressure,  reduced  need  for  escape  analgesia). 
The  number  of  trials  showing  a  positive  result  and  those 
showing  a  negative  result  should  be  given  together  with  a 
suitable  explanation. 
The  number  of  drop-outs  should  be  mentioned  together  with 
the  reason  for  drop-out. 
The  expected  and  unexpected  effects  of  therapeutic  doses  as 
well  as  overdoses  (if  information  is  available)  and  the  con-
tra  indications  are  to  be  described  and  compared  with  other 
drugs  with  analogous  effects. - 44  -
For  drugs  to  be  administered  long-term  attention  should  be 
paid  to  long-term  efficacy.  Regarding  fixed  ratio  combina-
tion  products  it  is  essential  to  include  commented  documen-
tation  showing  the  therapeutic  value  in  comparison  with  the 
single  ingredients,  when  taken  separately  in  therapeutic 
doses.  The  doses  of  the  individual  components  should  be  jus-
tified.  A  thorough  evaluation  of  such  a  product's  therapeu-
tic advantages  should  be  given. 
Insofar  as  chemical  incompatibilies  (e.g.  with  other  drugs 
and/or  solutions)  are  con~idered clinically relevant,  a  dis-
cussion  of  such  problems  should  be  included  in  the  reports. 
3.2.  Adverse  reactions,  tolerance  and  interactions 
Documentation  covering  adverse  reactions  (including clinical 
and  laboratory  changes),  should  be  exhaustive  and  their  re-
levance  and  profile  discussed.  The  number  of  patients  stu-
died,  the  dosage  regimens  (including  duration  of  treatment) 
and  methods  of  assessment  should  be  stated. 
If  there  is  a  different  spectrum  of  adverse  reactions  for 
different diseases  being  treated  this  should  be  pointed out. 
The  frequency  of  adverse  reactions  should  be  described  and 
should  be  compared  with  that of  the  reference  drugs. 
When  the  product  is  already on  the  market  in  some  countries, 
the  adverse  reactions  reported  and  the  figures  of  consumption 
in  these  countries  should  be  reported~ 
Interactions,  overdosage  reactions  and  intoxications,  drug 
dependence  potenti•al,  rebound  phenomena  after  discontinua-
tion  of  therapy,  I_:XJssible  use  during  pregnancy  and  breast 
feeding  and  possible  influence  on  e.g.  car  driving  should 
ali  be  considered. 
4.  Miscellaneous 
This  section  is  intended  for  information  not  covered  by  any 
of  the  previous  headings. 
5.  Conclusion 
In  this chapter  the  following  items  should  be  discussed: 
a.  rationale of  the  product  (especially  in  the  case  of  fixed 
combinations,  new  dosage  forms) i 
b.  efficacy; - 45  -
c.  safety  aspects  (e.g.  adverse  reactions,  contra  indica-
tions,  interactions,  warnings  and  precautions); 
d.  proposed  dosage, (range,  frequency,  age,  sex,  duration  of 
therapy,  etc.); 
e.  the  balance  between  the  benefits  and  the  risks  of  the 
product,  taking  the  results  of  the  pharmacological  and 
toxicological  tests  into  account. 
6.  Reference  list 
References  should  be  complete  and  formulated  in  accordance 
with  internationally accepted  standards,  and  include  all li-
terature cited. 
.... 
The  references  must  be  numbered  and  each  reference  should  be 
easily  located  in  the  application  file  in  question. 
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VI.  SAMPLE  PHARMACEUTICAL  EXPERTS  REPORTS  FORMS: PART  II  A 
Oeser iption  :  Page ( s)  -
Complete  composition  : 
Active  constituents 
Other  constituents 
I 
I 
! 
Container{s)  &  Closure(s) 
I 
I 
I 
I 
I 
r  Cl1nical  trial  formula (e)  I 
I 
I 
I 
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COMPOSITION 
Page(s)  -
(brief  description) 
:  Page ( s)  -
Pharmaceutical  Expert  report 
Form  1 
T 
COMMENT 
Page(s) 
I 
: 
: 
i 
I 
i 
I 
I 
I 
I 
! 
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PART  II  A  DOSAGE  FORM 
Development  Pharmaceutics  Page(S)  -
Pharmaceutical  Expert  report 
Form  2 
COMMENT PART  II  B 
Method  of  Preparation 
Dosage  Form.  Page ( s) 
Batch  size: 
Manufacturin9  formula: 
Manufacturing  ~recess 
: 
I 
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METHOD  OF  PREPARATION 
of 
Pharma ceut i caL  Expert  report 
Form  3 
COMMENT 
I 
I 
I -:  50  -
PART  II  B  DOSAGE  FORM 
Process  validation  Page(s)  -
Pharmaceutical  Expert  report 
Form  4 
COMMENT - 51  - Pharmaceutical  Expert  report 
Form  5 
PART  II  C  CONTROL  OF  STARTING  MATERIALS 
II  C  1.a.:  Active  constituents  (routine  tests)  COMMENT 
(a)  Active  constituents described  in  a  pharmacopoeia 
(b)  Active  constituents not  described  in  a  pharmacopoeia 
SPECIFICATION  AND  TEST  METHODS 
Appearance  :  Page(s) 
·Identity test (s)  :  Page (s) 
I  I 
Physical  test(s)  :  Page ( s) 
j  Chemical  test(s)  :  Page(s) 
I 
I 
I 
~Other test(sl  :  Page (s) 
I 
I 
I 
I 
Assay(s)  Page ( s) 
' 
I PART  II  C 
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Pharma ceut i caL  Expert  report 
Form  6 
CONTROL  OF  STARTING  MATERIALS 
II  C  l.b.:  ACTIVE  CONSTITUENTS  (DATA)  l 
I  r---------------------------------------------------1 
ACTIVE  CONSTITUENT 
1.  NOMENCLATURE  :  Page(s)  - .1  COMMENT 
---------------------------------------------------------- ---------------------------~·· 
Laboratory  Code  National  approved  name{s) 
I.N.N. 
I  I  I 
[  Chemical  ndme 
i 
! 
i 
Other  name(s) 
!  2.  DESCRIPTION  :  Page(s) 
[  Phys1cal  form 
I 
i  i 
I 
Structural  formula  I 
I 
I 
I 
I 
I 
I 
Molecular  formula  Molecular  weight 
j 
: 
I 
I 
I 
I 
I I 
I 
I 
i 
I 
i 
I 
I 
I 
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Form  7 
PART  II  C  CONTROL  OF  STARTING  MATERIALS 
r--------------------------------------------~-
II  C  l.b.:  ACTIVE  CONSTITUENTS  (DATA) 
3.  MANUFACTURE  COMMENT 
Synthetic  route(s)  :  Page (s) 
Description of  process  :  Page(s) 
Solvents  and  reagents 
Catalysts 
Final  purification 
4.  Quality  control  during  synthesis  Paqe(s) 
Starting materials  Specifications 
I 
I 
Intermediates  tested  Tests  Applied 
I - 54  - Pharmaceutical  Ex }Je r t  r e po  r t 
Form  a 
PART  II  C  CONTROL  OF  STARTING  MATERIALS 
II  C  l.b.:  ACTIVE  CONSTITUENTS  (DATA)  ... 
5.  DEVELOPMENT  CHEMISTRY 
Evidence  of  chemical  structure 
Synthetic 
rou  t_e 
Ke~.inter-
me  1ates 
1 
Elemental 
i 
ysis 
MS  ·~ 
NNR  ! 
IR 
w 
Other  methods  I 
Potential  isomerism  :  Page(s)  -
Asymmetric  I 
I 
I 
I  carbons 
I 
Optical 
rotation 
I  Cis-trans 
I 
Isomerism 
1  Threo-erythro 
isomerism  ,j 
Other  I 
isomers  I 
Physico-chemical  characterisation 
Solubility 
Physical 
characteristics 
Polymorphism 
pKa  and 
pH  values 
Other 
characteristics 
Analytical  development  Page(s) 
Page(s) 
:  Page(s) 
COMMENT 
-
I - 55  - Pharmaceutical 
PART  II  C  CONTROL  OF  STARTING  MATERIALS 
Expert  report 
Form  9 
II  C  1 .b.:  ACTIVE  CONSTITUENTS  (SCIENTIFIC  DATA) 
~-------------------------------------------------------------------------------------) 
6.  IMPURITIES 
Potential  impurities  :  Page(s)  Analytical  methods  of detection 
Impurities  found  :  Page(s) 
COMMENT - 56  - Pharmaceutical 
PART  II C  CONTROL  OF  STARTING  MATERIALS 
II c  1 .b.:  ACTIVE  CONSTITUENTS  (SCIENTIFIC  DATA) 
7.  BATCH  ANALYSIS 
Batches  tested  :  Page ( s)  -
Date ( s)  of  manufacture: 
Place(s)  of  manufacture: 
Batch  size (s)  andNo.(s) 
Use  of  batche(s) 
Results  :  .Page(s)  -
Batch  Nos 
Appearance: 
Identity test(s): 
Physical  test ( s): 
Chemical  test(s): 
Other  test ( s) : 
Assay(s): 
Reference  Standard  Page (s) 
Appearance: 
Identity  test(s): 
Physical  test (s): 
Chemical  test(s): 
Other  test ( s) : 
Assay(s): 
Expert  report 
Form  10 
COMMENT 
1 
I 
I 
I 
i 
! - 57  -
PART  II  C  CONTROL  OF  STARTING  MATERIALS 
II  C  2.a.:  OTHER  CONSTITUENTS  (ROUTINE  TESTS) 
(a)  Other  constituents described  in  a 
pharmacopoeia 
(b)  Other  constituents not  described  in 
a  pharmacoPOeia 
Pharmaceutical  Expert  report 
Form  11 
COMMENT 
I - 58  -
PART  II D  CONTROL  TESTS  ON  INTERMEDIATE  PRODUCTS 
PART  II  E  CONTROL  TESTS  ON  THE  FINISHED  PRODUCT: 
Page ( s}  -
Description  and  genera~ characteristics j 
I 
Identification  tests I 
Quantitativ·e  determination  of  active  ingredients  : 
page ( s}  -
I 
\ 
tests 
1 
Other  QC  I 
I 
I 
Identification  and  quantitatives determination  of 
other  constituents 
I 
I 
i 
L 
Pharmaceutical 
I 
Expert  report 
F'orm  12 
COM."\ENT  I 
I 
I 
I 
I 
I 
I 
: 
i 
i 
! 
! 
I 
I 
I 
I 
I 
l 
I 
I 
i 
I 
I 
i 
I 
I 
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PART  II  E  DOSAGE  FORM 
Control  tests on  finished  product 
Analytical validation  :  Page(s)  -
Pharmaceutical 
COMMENT 
Expert  report 
Form  13 
I - 60  -
PART  II  F  STABILITY 
Pharmaceutical  Expert  report 
Form  14 
Information  concerning  stability of  the  finished  product  (Page(s)  I 
t-------------1 
Number  of  batches  tested: 
Storaqe conditions: 
Description of containers: 
Results  of  Tests 
Analytical  methods  (if different  to  those  in  Part  II  E): 
I 
f--
Proposed  shelf-life  and  storage  precautions 
COMMENT: 
I - 61  - Pharmaceutical Expert  report 
Form  15 
STABILITY 
1  l 
~----------------
PART  II  F 
Stability tests on  active constituent 
~--------------------------------------~~~--------------------------------------------------
Batches  examined  :  Page(s)  -
Conditions  of  storage  Results 
Analytical  methods - 62  -
VII~  SAMPLE  EXPERT  REPORT  TABLES: 
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